HUE048750T2 - (R)-3-((3S,4S)-3-fluor-4-(4-hidroxifenil)piperidin-l-il)-l-(4-metilbenzil)pirrolodin-2-on és prodrugjai pszichiátriai rendellenességek kezelésére - Google Patents
(R)-3-((3S,4S)-3-fluor-4-(4-hidroxifenil)piperidin-l-il)-l-(4-metilbenzil)pirrolodin-2-on és prodrugjai pszichiátriai rendellenességek kezeléséreInfo
- Publication number
- HUE048750T2 HUE048750T2 HUE15702312A HUE15702312A HUE048750T2 HU E048750 T2 HUE048750 T2 HU E048750T2 HU E15702312 A HUE15702312 A HU E15702312A HU E15702312 A HUE15702312 A HU E15702312A HU E048750 T2 HUE048750 T2 HU E048750T2
- Authority
- HU
- Hungary
- Prior art keywords
- pyrrolodin
- methylbenzyl
- piperidin
- prodrugs
- hydroxyphenyl
- Prior art date
Links
- -1 (3S, 4S) -3-fluoro-4- (4-hydroxyphenyl) piperidin-1-yl Chemical group 0.000 title 1
- 125000006181 4-methyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])C([H])([H])* 0.000 title 1
- 229940002612 prodrug Drugs 0.000 title 1
- 239000000651 prodrug Substances 0.000 title 1
- 208000020016 psychiatric disease Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/59—Hydrogenated pyridine rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461925405P | 2014-01-09 | 2014-01-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE048750T2 true HUE048750T2 (hu) | 2020-08-28 |
Family
ID=52444626
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE15702312A HUE048750T2 (hu) | 2014-01-09 | 2015-01-08 | (R)-3-((3S,4S)-3-fluor-4-(4-hidroxifenil)piperidin-l-il)-l-(4-metilbenzil)pirrolodin-2-on és prodrugjai pszichiátriai rendellenességek kezelésére |
Country Status (27)
| Country | Link |
|---|---|
| US (10) | US9187506B2 (enExample) |
| EP (2) | EP3677578A1 (enExample) |
| JP (1) | JP6629738B2 (enExample) |
| KR (1) | KR102331120B1 (enExample) |
| AR (1) | AR102019A1 (enExample) |
| AU (1) | AU2015204785A1 (enExample) |
| CA (1) | CA2936338A1 (enExample) |
| CL (1) | CL2016001744A1 (enExample) |
| CY (1) | CY1122768T1 (enExample) |
| DK (1) | DK3092223T3 (enExample) |
| EA (1) | EA201691133A1 (enExample) |
| ES (1) | ES2771825T3 (enExample) |
| HR (1) | HRP20200161T1 (enExample) |
| HU (1) | HUE048750T2 (enExample) |
| IL (1) | IL246596A0 (enExample) |
| LT (1) | LT3092223T (enExample) |
| MX (1) | MX2016008715A (enExample) |
| PE (1) | PE20160898A1 (enExample) |
| PL (1) | PL3092223T3 (enExample) |
| PT (1) | PT3092223T (enExample) |
| RS (1) | RS59858B1 (enExample) |
| SG (1) | SG11201605620QA (enExample) |
| SI (1) | SI3092223T1 (enExample) |
| SM (1) | SMT202000094T1 (enExample) |
| TW (1) | TW201612169A (enExample) |
| UY (1) | UY35946A (enExample) |
| WO (1) | WO2015105929A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9187506B2 (en) * | 2014-01-09 | 2015-11-17 | Bristol-Myers Squibb Company | (R)-3-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and its prodrugs for the treatment of psychiatric disorders |
| MX2018004256A (es) | 2015-10-14 | 2018-05-16 | Squibb Bristol Myers Co | Antagonistas de receptor de n-metil-d-aspartato subtipo 2b (nr2b) selectivos. |
| CA3001894A1 (en) * | 2015-10-14 | 2017-04-20 | Bristol-Myers Squibb Company | Selective nr2b antagonists |
| US12086719B2 (en) * | 2019-10-11 | 2024-09-10 | Royal Bank Of Canada | System and method of machine learning using embedding networks |
| WO2024197289A1 (en) * | 2023-03-22 | 2024-09-26 | Gilgamesh Pharmaceuticals, Inc. | Negative allosteric modulators of glun2b receptors and methods of making and using the same |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6476041B1 (en) | 1999-10-29 | 2002-11-05 | Merck & Co., Inc. | 1,4 substituted piperidinyl NMDA/NR2B antagonists |
| MXPA02009659A (es) | 2000-04-26 | 2003-03-10 | Warner Lambert Co | Derivado de ciclohexilamina como subtipo de los antagonistas del receptor selectivo nmda. |
| JPWO2003035641A1 (ja) | 2001-10-22 | 2005-02-10 | 塩野義製薬株式会社 | 新規カルバモイルピロリドン誘導体 |
| KR20060017839A (ko) | 2003-06-04 | 2006-02-27 | 머크 앤드 캄파니 인코포레이티드 | Ｎｍｄａ／ｎｒ2ｂ 길항제로서 3-플루오로-피페리딘 |
| MXPA06003748A (es) | 2003-10-08 | 2006-06-14 | Pfizer | Compuestos de lactama condensada. |
| EP2520567A3 (en) | 2006-02-23 | 2012-12-12 | Shionogi & Co., Ltd. | Nitrogen-containing heterocycle derivatives substituted with cyclic group |
| KR20100045983A (ko) | 2007-06-29 | 2010-05-04 | 에모리 유니버시티 | 신경보호를 위한 ｎｍｄａ 수용체 길항물질 |
| CN102036985A (zh) * | 2007-11-13 | 2011-04-27 | 沃泰克斯药物股份有限公司 | 用于治疗疼痛的作为离子通道调节剂的4(-3-(-2-(苯基)吗啉代)-2-氧代吡咯烷-1-基)-n-(噻唑-2-基)苯磺酰胺衍生物和相关化合物 |
| US9187506B2 (en) * | 2014-01-09 | 2015-11-17 | Bristol-Myers Squibb Company | (R)-3-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and its prodrugs for the treatment of psychiatric disorders |
-
2015
- 2015-01-07 US US14/591,372 patent/US9187506B2/en active Active
- 2015-01-08 SG SG11201605620QA patent/SG11201605620QA/en unknown
- 2015-01-08 TW TW104100590A patent/TW201612169A/zh unknown
- 2015-01-08 CA CA2936338A patent/CA2936338A1/en not_active Abandoned
- 2015-01-08 AU AU2015204785A patent/AU2015204785A1/en not_active Abandoned
- 2015-01-08 MX MX2016008715A patent/MX2016008715A/es unknown
- 2015-01-08 LT LTEP15702312.8T patent/LT3092223T/lt unknown
- 2015-01-08 PE PE2016001105A patent/PE20160898A1/es unknown
- 2015-01-08 DK DK15702312.8T patent/DK3092223T3/da active
- 2015-01-08 JP JP2016545818A patent/JP6629738B2/ja not_active Expired - Fee Related
- 2015-01-08 PL PL15702312T patent/PL3092223T3/pl unknown
- 2015-01-08 SI SI201531064T patent/SI3092223T1/sl unknown
- 2015-01-08 KR KR1020167021355A patent/KR102331120B1/ko not_active Expired - Fee Related
- 2015-01-08 EP EP19212924.5A patent/EP3677578A1/en not_active Withdrawn
- 2015-01-08 HR HRP20200161TT patent/HRP20200161T1/hr unknown
- 2015-01-08 RS RS20200109A patent/RS59858B1/sr unknown
- 2015-01-08 ES ES15702312T patent/ES2771825T3/es active Active
- 2015-01-08 PT PT157023128T patent/PT3092223T/pt unknown
- 2015-01-08 EP EP15702312.8A patent/EP3092223B1/en active Active
- 2015-01-08 WO PCT/US2015/010552 patent/WO2015105929A1/en not_active Ceased
- 2015-01-08 SM SM20200094T patent/SMT202000094T1/it unknown
- 2015-01-08 EA EA201691133A patent/EA201691133A1/ru unknown
- 2015-01-08 HU HUE15702312A patent/HUE048750T2/hu unknown
- 2015-01-09 AR ARP150100067A patent/AR102019A1/es unknown
- 2015-01-09 UY UY0001035946A patent/UY35946A/es unknown
- 2015-10-13 US US14/881,932 patent/US20160030456A1/en not_active Abandoned
-
2016
- 2016-07-04 IL IL246596A patent/IL246596A0/en unknown
- 2016-07-07 CL CL2016001744A patent/CL2016001744A1/es unknown
- 2016-11-21 US US15/357,102 patent/US20170065573A1/en not_active Abandoned
-
2017
- 2017-04-18 US US15/490,558 patent/US20170216325A1/en not_active Abandoned
- 2017-08-17 US US15/679,847 patent/US20170340653A1/en not_active Abandoned
- 2017-12-19 US US15/846,914 patent/US20180104265A1/en not_active Abandoned
-
2018
- 2018-05-04 US US15/971,049 patent/US20180250316A1/en not_active Abandoned
- 2018-12-19 US US16/225,631 patent/US20190125770A1/en not_active Abandoned
-
2019
- 2019-06-27 US US16/454,843 patent/US20190314392A1/en not_active Abandoned
-
2020
- 2020-01-31 US US16/778,960 patent/US20200297742A1/en not_active Abandoned
- 2020-02-07 CY CY20201100120T patent/CY1122768T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUS2400030I1 (hu) | Aril, heteroaril és heterociklusos vegyületek komplement által közvetített rendellenességek kezelésére | |
| IL264049A (en) | Compounds, preparations and methods for treating the disease | |
| IL264156A (en) | Compounds, preparations and methods for treating the disease | |
| HUE059163T2 (hu) | Szabályozható transzkripció | |
| HUE050155T2 (hu) | 1-tetrahidropiranilkarbonil-2,3-dihidro-1H-indol vegyületek rák kezelésére | |
| JP2016028092A5 (enExample) | ||
| LT3261640T (lt) | 5ht agonistai epilepsijos sutrikimų gydymui | |
| LT3250210T (lt) | Kompozicijos ir būdai, skirti gydyti cns sutrikimus | |
| HUE053191T2 (hu) | 2-Heteroaril-3-oxo-2,3-dihidropiridazin-4-karboxamidok rák kezelésére | |
| JP2016065085A5 (enExample) | ||
| LT3390390T (lt) | Bipirazolilo dariniai, tinkami naudoti autoimuninių ligų gydymui | |
| LT3416957T (lt) | 6-heterociklil-4-morfolin-4-ilpiridin-2-ono junginiai, tinkami vėžio ir diabeto gydymui | |
| PT3579826T (pt) | Métodos de tratamento de distúrbios de cdkl5 com o composto ov329 | |
| IL283948A (en) | Methods for treating depression | |
| DK3463351T3 (da) | Behandling til parkinsons sygdom | |
| LT3377094T (lt) | Susilpninto virulentiškumo bakterijos, skirtos piktybinių solidinių navikų gydymui | |
| GB201612165D0 (en) | Combinations for the treatment of type 2 diabetes | |
| DK3506956T3 (da) | Lægemiddel, særlig til behandling af fistler | |
| IL246596A0 (en) | ((r)-3-((3s, 4s)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and prodrugs for the treatment of psychiatric disorders | |
| HUE046116T2 (hu) | Biotin, demielinizációs neuropátiák kezelésére | |
| PL3484475T3 (pl) | 1-Metylonikotynamid do leczenia choroby układu krążenia | |
| LT3413870T (lt) | Igmesinas, skirtas panaudoti alzheimerio ligos gydymui | |
| HUE053358T2 (hu) | 5-Metil-6-fenil-4,5-dihidro-2H-piridazin-3-on származék agytumorok kezelésére | |
| EP3532044A4 (en) | HDAC INHIBITOR COMPOSITIONS FOR CHROMOSOME X REACTIVATION | |
| LT3290436T (lt) | Fenilalanino neturintis baltymas, skirtas fenilketonurijos gydymui |